The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.
Amir Abbas Tahami MonfaredAli TafazzoliAmeya ChavanWeicheng YeQuanwu ZhangPublished in: Neurology and therapy (2022)
The early model predicted that lecanemab would potentially improve long-term health outcomes and reduce formal and informal care costs, resulting in a range of VBPs that reflect the value of lecanemab to society.